The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Open accessAbstract
PURPOSE: Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging. Mutations in the isocitrate dehydrogenase 1 ( IDH1) gene occur in most LGGs (> 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients with solid tumors. METHODS: We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with m IDH1 solid tumors. Ivosidenib was administered orally daily in 28-day cycles. RESULTS: In 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached; 500 mg once per day was selected for the expansion cohort. The grade ≥ 3 adverse event rate was 19.7%; 3% (n = 2) were considered treatment related. In patients with nonenhancing glioma (n = 35), the objective response rate was 2.9%, with 1 partial response. Thirty of 35 patients (85.7%) with nonenhancing glioma achieved stable disease compared with 14 of 31 (45.2%) with enhancing glioma. Median progression-free survival was 13.6 months (95% CI, 9.2 to 33.2 months) and 1.4 months (95% CI, 1.0 to 1.9 months) for the nonenhancing and enhancing glioma cohorts, respectively. In an exploratory analysis, ivosidenib reduced the volume and growth rates of nonenhancing tumors. CONCLUSION: In patients with m IDH1 advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Fitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationWen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Self-citationComprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974
Self-citationEnasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Stein, E. M., DiNardo, C. D., Pollyea, D. A., Fathi, A. T., Roboz, G. J., Altman, J. K., Stone, R. M., DeAngelo, D. J., Levine, R. L., Flinn, I. W., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779405 · Cited by 1,516
Self-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Self-citationAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Self-citationWeller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Buckner, J. C., Shaw, E. G., Pugh, S. L., Chakravarti, A., Gilbert, M. R., Barger, G. R., Coons, S., Ricci, P., Bullard, D., Brown, P. D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1500925 · Cited by 1,064
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Self-citation( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
(2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 663
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Self-citationContinuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493
Novel, improved grading system(s) for IDH-mutant astrocytic gliomas
Shirahata, M., Ono, T., Stichel, D., Schrimpf, D., Reuss, D. E., Sahm, F., Koelsche, C., Wefers, A., Reinhardt, A., Huang, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1849-4 · Cited by 457
van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J. B., Wesseling, P., Frenay, M., Tijssen, C. C., Lacombe, D., Idbaih, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2902 · Cited by 381
Kosmider, O., Gelsi-Boyer, V, Slama, L., Dreyfus, F., Beyne-Rauzy, O., Quesnel, B., Hunault-Berger, M., Slama, B., Vey, N., Lacombe, C., et al. (2010) · Leukemia · doi:10.1038/leu.2010.52 · Cited by 247
Lowery, M. A., Burris, H. A., Janku, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 224
Self-citationIDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
Dubbink, H. J., Taal, W., van Marion, R., Kros, J. M., van Heuvel, I., Bromberg, J. E., Zonnenberg, B. A., Zonnenberg, C. B. L., Postma, T. J., Gijtenbeek, J. M. M., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c34ace · Cited by 188
Diffuse Infiltrating Oligodendroglioma and Astrocytoma
van den Bent, M. J., Smits, M., Kros, J. M., & Chang, S. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6737 · Cited by 172
Jonsson, P., Lin, A. L., Young, R. J., DiStefano, N. M., Hyman, D. M., Li, B. T., Berger, M. F., Zehir, A., Ladanyi, M., Solit, D. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0032 · Cited by 169
Self-citationTap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02492 · Cited by 165
Self-citationRees, J. H., Watt, H., Jäger, H. R., Benton, C., Tozer, D. J., Tofts, P. S., & Waldman, A. D. (2008) · European Journal of Radiology · doi:10.1016/j.ejrad.2008.06.013 · Cited by 162
Pallud, J., Taillandier, L., Capelle, L., Fontaine, D., Peyre, M., Ducray, F., Duffau, H., & Mandonnet, E. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31826213de · Cited by 135
Ellingson, B. M., Leu, K., Pope, W. B., Lai, A., Nghiemphu, P. L., Liau, L. M., & Cloughesy, T. F. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov225.24 · Cited by 98
Self-citationFan, B., Mellinghoff, I. K., Wen, P. Y., Lowery, M. A., Goyal, L., Tap, W. D., Pandya, S. S., Manyak, E. L., Jiang, L., Liu, G., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00771-x · Cited by 94
Self-citationImpact of MRI head placement on glioma response assessment
Reuter, M., Gerstner, E. R., Rapalino, O., Batchelor, T. T., Rosen, B. R., & Fischl, B. R. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1403-8 · Cited by 47
Freyschlag, C. F., Krieg, S. M., Kerschbaumer, J., Pinggera, D., Forster, M.-T., Cordier, D., Rossi, M., Miceli, G., Roux, A., Reyes, A. F., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2916-3 · Cited by 37
Cited by
Glioblastoma and Other Primary Brain Malignancies in Adults: A Review
Schaff, L. R., & Mellinghoff, I. K. (2023) · JAMA · doi:10.1001/jama.2023.0023 · Cited by 1,271
Self-citationVorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Mellinghoff, I. K., van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304194 · Cited by 814
Self-citationWeller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Self-citationIvosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia
Montesinos, P., Recher, C., Vives, S., Zarzycka, E., Wang, J., Bertani, G., Heuser, M., Calado, R. T., Schuh, A. C., Yeh, S.-P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117344 · Cited by 514
Self-citationDiffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Metadata
- Authors
- Mellinghoff, I. K., Ellingson, B. M., Touat, M., Maher, E., De La Fuente, M. I., Holdhoff, M., Cote, G. M., Burris, H., Janku, F., Young, R. J., Huang, R., Jiang, L., Choe, S., Fan, B., Yen, K., Lu, M., Bowden, C., Steelman, L., Pandya, S. S., Cloughesy, T. F., & Wen, P. Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-10-10
- Volume
- 38
- Issue
- 29
- Pages
- 3398-3406
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3034266209
- Cited by
- 324
- References
- 43
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.